Anebulo Pharmaceuticals, Inc. (ANEB) - Dilution Analysis

8-K filing: Anebulo Pharmaceuticals, Inc. announced the preliminary results of its tender offer to purchase for cash up to 300,000 shares of its common stock at a purchase price of $3.50 per share, which expired on January 26, 2026. ($1.05M proceeds)

8-K filing: Anebulo Pharmaceuticals announced a tender offer to purchase up to 300,000 shares of its common stock at $3.50 per share for an aggregate purchase price of up to $1,050,000 and abandoned a previously proposed reverse stock split. ($1.05M proceeds)

10-Q filing | 41.1M shares outstanding

10-K filing | 41.1M shares outstanding

POS AM filing: This POS AM filing indicates the removal from registration of any and all shares of the Company's Common Stock registered but unsold under the Registration Statement as of the filing date.

10-Q filing | 41.1M shares outstanding

8-K filing: Anebulo Pharmaceuticals, Inc. entered into a lock-up agreement with 22NW Fund, LP regarding previously issued shares and executed an irrevocable letter instructing the transfer agent to restrict the voting and sale of these shares until stockholder approval.

S-3 filing: This S-3 filing relates to the resale from time to time of up to an aggregate of 15,151,514 shares of common stock of Anebulo Pharmaceuticals, Inc. by the selling stockholders.

10-Q filing | 41.1M shares outstanding

8-K filing: Anebulo Pharmaceuticals, Inc. completed a private placement on December 23, 2024, issuing 15,151,514 shares of common stock at a price of $0.99 per share, resulting in gross proceeds of approximately $15 million. ($15.0M proceeds)

10-Q filing | 25.9M shares outstanding

10-K filing | 25.8M shares outstanding

8-K filing: Anebulo Pharmaceuticals, Inc. approved a new non-employee director equity compensation policy providing for initial and annual equity awards of options to purchase shares of the Company's common stock.

10-Q filing | 25.9M shares outstanding

10-Q filing | 25.8M shares outstanding

10-Q filing | 25.6M shares outstanding

10-K filing | 25.1M shares outstanding

10-Q filing | 25.6M shares outstanding

10-Q filing | 25.6M shares outstanding

10-Q filing | 23.4M shares outstanding

S-1 filing: The filing discusses a private placement of series A preferred stock convertible into common stock, the purchase of milestone warrants exercisable for series A preferred stock, and a private placement of units consisting of common stock and warrants to purchase common stock.

8-K filing: Anebulo Pharmaceuticals, Inc. completed a private placement on September 28, 2022, selling 2,264,650 units, each consisting of one share of common stock and a warrant, to institutional accredited investors for approximately $6.6 million. ($13.2M proceeds)

10-K filing | 23.3M shares outstanding

10-Q filing | 23.3M shares outstanding

10-Q filing | 23.3M shares outstanding

10-Q filing | 23.3M shares outstanding

10-K filing | 23.3M shares outstanding

10-Q filing | 23.3M shares outstanding

S-1/A filing: This S-1/A filing describes an exclusive worldwide license agreement, a private placement of series A preferred stock convertible into common stock, and milestone warrants exercisable for series A preferred stock.

S-1/A filing: This S-1/A filing details an initial public offering of Anebulo Pharmaceuticals, Inc. for 3,000,000 shares of common stock, with an additional 450,000 shares available through an underwriter option, and indicates planned purchases by 22NW, LP and Vernalis Development Limited.

S-1 filing: This S-1 filing describes an exclusive license agreement, a private placement of series A preferred stock convertible into common stock, and milestone warrants exercisable for series A preferred stock.